http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Walid S. Ibrahim (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Walid S. Ibrahim,Zeiad H. Eldaly,Mahmoud F. Rateb,Ahmed H. Aldoghaimy,Mohamed G. Saleh 대한안과학회 2019 Korean Journal of Ophthalmology Vol.33 No.2
Purpose: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimalresponse to previous anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: A prospective interventional case series study recruited patients from a single center diagnosedwith DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of afliberceptwere performed. The primary outcome measure was mean change in visual acuity after switching toaflibercept. Results: Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution(logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ±0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57± 107.09 μm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03,328.24 ± 81.98, and 313.71 ± 85.79 μm, respectively). Both visual improvement and mean change in retinalthickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMARbut were not significant in patients with best-corrected visual acuity more than 1.0 logMAR. Conclusions: Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGFinjections provided acceptable short-term visual and retinal architectural improvement.
-
Walid S,Ibrahim,Zeiad H,Eldaly,Mohamed G,Saleh,Mahmoud F,Rateb,Ahmed H,Aldoghaimy 대한안과학회 2019 Korean Journal of Ophthalmology Vol.33 No.2
Purpose: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: A prospective interventional case series study recruited patients from a single center diagnosed with DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of aflibercept were performed. The primary outcome measure was mean change in visual acuity after switching to aflibercept. Results: Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution(logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ± 0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57± 107.09 μm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03, 328.24 ± 81.98, and 313.71 ± 85.79 μm, respectively). Both visual improvement and mean change in retinal thickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMAR but were not significant in patients with best-corrected visual acuity more than 1.0 logMAR. Conclusions: Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGF injections provided acceptable short-term visual and retinal architectural improvement.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
